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Background: Substantial complexity has been introduced into treatment regimens for patients 
with human immunodeficiency virus (HIV) infection. Many drug-related problems (DRPs) are 
detected in these patients, such as low adherence, therapeutic inefficacy, and safety issues. We 
evaluated the impact of pharmacist interventions on CD4+ T-lymphocyte count, HIV viral load, 
and DRPs in patients with HIV infection.
Methods: In this 18-month prospective controlled study, 90 outpatients were selected by 
convenience sampling from the Hospital Dia–University of Campinas Teaching Hospital 
(Brazil). Forty-five patients comprised the pharmacist intervention group and 45 the control 
group; all patients had HIV infection with or without acquired immunodeficiency syndrome. 
Pharmaceutical appointments were conducted based on the Pharmacotherapy Workup method, 
although DRPs and pharmacist intervention classifications were modified for applicability to 
institutional service limitations and research requirements. Pharmacist interventions were per-
formed immediately after detection of DRPs. The main outcome measures were DRPs, CD4+ 
T-lymphocyte count, and HIV viral load.
Results: After pharmacist intervention, DRPs decreased from 5.2 (95% confidence interval 
[CI] =4.1–6.2) to 4.2 (95% CI =3.3–5.1) per patient (P=0.043). A total of 122 pharmacist inter-
ventions were proposed, with an average of 2.7 interventions per patient. All the pharmacist 
interventions were accepted by physicians, and among patients, the interventions were well 
accepted during the appointments, but compliance with the interventions was not measured. 
A statistically significant increase in CD4+ T-lymphocyte count in the intervention group was 
found (260.7 cells/mm3 [95% CI =175.8–345.6] to 312.0 cells/mm3 [95% CI =23.5–40.6], 
P=0.015), which was not observed in the control group. There was no statistical difference 
between the groups regarding HIV viral load.
Conclusion: This study suggests that pharmacist interventions in patients with HIV infection 
can cause an increase in CD4+ T-lymphocyte counts and a decrease in DRPs, demonstrating 
the importance of an optimal pharmaceutical care plan.
Keywords: pharmaceutical care, HIV, clinical pharmacy, CD4+ T lymphocyte count, AIDS, 
pharmacy service
Introduction
With the increasing number, availability, and rapid emergence of new information on 
antiretroviral (ARV) agents, a substantial complexity has been introduced into treatment 
regimens for patients with human immunodeficiency virus (HIV) infection.1 This may 
lead to low adherence to ARV regimens, which directly affects therapeutic efficacy. The 
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risk of treatment failure, commonly associated with resistance 
to ARV agents, increases as adherence to therapy decreas-
es.2 Clinical parameters used as predictors of therapeutic 
efficacy are CD4+ T-lymphocyte count and HIV viral load. 
CD4+ T-lymphocyte count is the most significant predictor 
of disease  progression and survival. Lower CD4+ counts 
are associated with a greater risk of disease progression.3,4 
CD4+ counts from 350 to 500 cells/mm3 are associated 
with risks of 5% across all age and HIV ribonucleic acid 
strata, whereas the risk of acquired immunodeficiency syn-
drome (AIDS) progression substantially increases at CD4+ 
counts 350 cells/mm3. The greatest risk increase occurs as 
CD4+ counts fall to 200 cells/mm3.3,5
Due to ARV regimen complexity, many drug-related prob-
lems (DRPs) are detected in both inpatients and outpatients.6–8 
A DRP is an undesirable patient experience involving drug 
therapy that actually or potentially interferes with the desired 
patient outcome. The pharmacist is a key professional in 
detecting and preventing DRPs by providing information, 
answering questions, and helping the patient to improve his 
or her self-care. In this context, the function assigned to the 
pharmacist-educator is one of the most important to promote 
the rational use of medicines.6,7,9,10
The public health system in Brazil is internationally 
recognized for its delivery of optimal treatment to patients 
with HIV at no cost since 1996. It is estimated that 217,000 
patients have already been treated.11,12 Many similarities are 
observed when comparing Brazilian and American HIV treat-
ment guidelines, suggesting that both can provide optimal 
care to patients with HIV (Table 1).4,13
However, suboptimal adherence to drug therapy greatly 
contributes to viral resistance and treatment failure.14 
Table 1 Comparison of the Brazilian and United Stated guidelines for human immunodeficiency virus treatment in relation to drug-
resistance testing at the time of antiretroviral therapy (ART) initiation, initiating ART in treatment-naïve patients, and initial combination 
regimens for antiretroviral-naïve patients
Drug-resistance testing at  
the time of ART initiation
Initiating ART in treatment-naïve patients Initial combination regimens for 
antiretroviral-naïve patients
Brazil4 People infected by partner  
in use of ART (recent or in  
the past); pregnant women with  
HIV infection
All patients with HIV infection with symptomatic HIV;  
active tuberculosis; CD4+ count 500 cells/mm3;  
coinfection with hepatitis B virus; pregnant women; 
established cardiovascular disease; AIDS-defining 
malignancies with no indication of chemotherapy or 
radiotherapy.
AZT/3TC + EFV or TDF/3TC + EFV, 
regarding each patient’s characteristics 
and presence of renal dysfunction or 
anemia not related to HIV infection.
United  
States13
People with HIV infection at entry  
into care regardless of whether 
ART was initiated immediately  
or deferred/pregnant women  
with HIV infection
All patients with HIV infection, to reduce  
the risk of disease progression.
1) Based on the NNRTI: EFV/TDF/FTC
2)  Based on PI/r: ATV/r + TDF/FTC 
or DRV/r + TDF/FTC
3)  Based on integrase inhibitor:  
RAL + TDF/FTC.
Abbreviations: AIDS, acquired immunodeficiency syndrome; ATV/r + TDF/FTC, atazanavir/ritonavir + tenofovir/emtricitabine; AZT/3TC, zidovudine/efavirenz; DRV/r + TDF/
FTC, darunavir/ritonavir + tenofovir/emtricitabine; EFV, efavirenz; EFV/TDF/FTC, efavirenz/tenofovir/emtricitabine; HIV, human immunodeficiency virus; NNRTI, nonnucleoside 
reverse transcriptase inhibitor; PI/r, protease inhibitors/ritonavir; RAL + TDF/FTC, raltegravir + tenofovir/emtricitabine; TDF/3TC, tenofovir/lamivudine.
In an effort to slow viral resistance; improve treatment 
 effectiveness; and identify, prevent, and solve DRPs,  clinical 
pharmacist intervention can be of benefit to patients with 
HIV.10,15 Several studies with various population profiles 
demonstrated a significant decrease in medication errors 
at institutions where pharmacists performed interventions 
alongside the clinical team.10,16–19 A systematic review and 
meta-analysis showed that pharmacists providing direct 
patient care had favorable effects across various patient 
outcomes, health care settings, and disease states.20
Clinical pharmacy began to be officially discussed in 
Brazil in the mid-1990s. Since then, clinical pharmacy 
and pharmaceutical care services have been introduced in 
group discussions and research throughout the country in 
both private and public institutions, resulting in important 
developments in the field.21,22 Academically, general phar-
macists are trained to work in various profession areas, and 
clinical pharmacists can now specialize. As is the case in 
many countries, more studies assessing the impact of clinical 
pharmacy services in Brazil are needed on patient outcomes 
and safety.23,24
This article contributes to the literature in many ways. Its 
purpose is to verify the relevance of performing pharmacy 
care in patients with HIV infection through the analysis of 
its effect on DRPs, CD4+ T-lymphocyte counts, and HIV 
viral load.
Materials and methods
In this prospective controlled study, patients were selected by 
convenience sampling between February 2009 and August 
2010 at the Hospital Dia–University of Campinas Teaching 
Hospital (Campinas, Brazil). The research was approved by 
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the Research Ethics Committee of the Faculty of Medical 
Sciences, University of Campinas.
Eligibility criteria
Outpatients with HIV or AIDS aged 18–60 years and with 
a body mass index of 30 kg/m2 were eligible if they were 
receiving ARV treatment with no changes at the inclusion 
visit or within the previous 4 weeks. Patients aged 60 years 
were not included in the study because higher HIV infec-
tion progression and mortality rates have been identified 
among older patients compared with younger patients.25 
 Additionally, advanced age is associated with a greater 
number of medications for comorbidities, drug interactions, 
adverse reactions, and toxicity.26 Obese patients were not 
included because they present higher incidences of hyper-
lipidemia, hypertension, and insulin resistance, and because 
some HIV medications, such as protease inhibitors, can cause 
weight gain and fat accumulation, it would not be possible to 
determine whether weight gain was related to the medication 
or to the background disease in such patients.27–30
Excluded from participation were patients who were 
prisoners, who were unable to return for appointments or 
examinations, who died during the study period, who had 
severe psychiatric disease that limited comprehension, who 
did not follow previously scheduled appointments, and who 
were pregnant.
Groups, outcome measures,  
and classifications
Patients were assigned to an intervention group or a control 
group. On days when the clinical pharmacy team was in 
Hospital Dia for appointments, medical charts of patients 
being attended were analyzed for fit with the study criteria, 
and those eligible were assigned to the intervention group. 
On days when the clinical pharmacy staff was not in Hospital 
Dia, patients were evaluated for eligibility and assigned to 
the control which was subsequently revised by the clinical 
pharmacy team.
Patients in the intervention group were asked to attend 
appointments with a clinical pharmacist after their routine 
physician appointments during the study period. Those in the 
control group received the usual care without appointments 
with the clinical pharmacists.
For the intervention group, at least two pharmacist 
appointments of 30–60 minutes each were performed. The first 
appointment was named visit one. Visit two was defined as the 
second pharmacist appointment with new CD4+ count and 
HIV viral load results. Some patients attended more than one 
pharmacist appointment after visit one, but for study  purposes, 
only visits defined as one and two were considered. For the 
control group, visits one and two were defined as medical 
appointments that included examination results. Patients in 
the intervention group who had fewer than two pharmacist 
appointments and patients in both groups who were referred 
to another health service during the study were excluded.
Pharmacist appointments began with data collection 
through patient interview regarding medical history. Besides 
patient reports about health and ongoing treatments, other 
information was obtained from family members or caregivers 
and other health professionals. The theoretical framework for 
the pharmaceutical appointment relied on Pharmacotherapy 
Workup, a process where pharmacists use rational decision-
making to assess a patient’s drug-related needs, identify drug 
therapy problems, develop a care plan, conduct follow-up 
evaluations, and ensure that all drug therapies are safe and 
effective.31 The Pharmacotherapy Workup was modified 
according to our institution’s service limitations and research 
requirements. Forms used to record data and guide the pharma-
cist appointments were prepared by the study pharmacists.
The pharmacist team comprised two pharmacists respon-
sible for performing the clinical pharmacist appointments and 
two pharmacists responsible for DRP analysis. The primary 
end point was the comparison between DRPs identified at 
baseline and at the end of the study for the intervention group. 
Secondary end points were the comparison between change 
in CD4+ and HIV viral load from baseline to study end in 
both the intervention and the control groups.
Before the pharmacist appointments, the patient’s medi-
cal history was reviewed using his or her medical chart. The 
following data were collected for each intervention group 
patient: age, ethnicity, HIV diagnosis in years, HIV treat-
ment in years, CD4+ count, HIV viral load, comorbidities, 
and ARV regimen. Patient symptoms, signs, complaints, 
medications in use, and self-reported nonadherence data 
were obtained through an interview during the pharmacist 
appointment. These data were analyzed by separate pharma-
cists on the team to identify and classify the DRPs related 
to all medications, including ARV therapy. For the control 
group, the same data were collected from the medical chart 
at the time when the patient was included in the study, but the 
pharmacist appointment was not performed, and additional 
data regarding medication were not collected; thus, the DRPs 
could not be accurately identified.
DRPs were individually identified and classified by two 
pharmacists, in seven categories: 1) unnecessary drug  therapy: 
drug therapy is unnecessary because there is no clinical 
 indication; 2) needs additional drug therapy:  additional drug 
therapy is required to treat or prevent a  medical  condition; 
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3) ineffective drug: drug is not effective in producing the 
desired response; 4) dosage too low: dosage is too low to 
produce the desired response; 5) adverse drug reaction: 
drug causes an adverse reaction; 6) dosage too high: dosage 
results in undesirable effects; 7) noncompliance: the patient 
is not able or willing to take the drug regimen appropriately.31 
After identifying DRPs, the clinical pharmacists developed a 
pharmacist intervention plan comprising measures to be taken 
by the patient and medical team in upcoming appointments. 
The three main pharmacist goals were to resolve DRPs, 
prevent DRPs, and encourage the adoption of healthy habits 
(quality-of-life intervention).
Pharmacist interventions consisted of guiding patients, 
mainly with regard to adherence to the prescribed therapeutic 
regimen, and suggesting medication changes to physicians 
when needed. Pharmacist interventions were performed in 
case of problems with dosage, drug–drug and drug–food 
interactions, side effects, and adverse reactions. Verbal and 
written information about pharmaceutical interventions was 
provided to the patients and physicians.
A community pharmacy specializing in ARV treatment, 
also located at the University of Campinas, was responsible 
for providing the ARV treatment.
Statistical analysis
A 95% confidence interval (CI) was applied to determine the 
extent of variation in data. Collected data were analyzed using 
a paired t-test to compare primary and secondary end points 
before and after interventions. For nonparametric data and 
because of the small sample size, DRP reduction, total phar-
macist interventions, increase of CD4+ T-lymphocyte count, 
and reduction in HIV viral load for the intervention group were 
analyzed by Spearman correlation test. A two-sided P0.05 
was considered statistically significant for all tests.
Results
A total of 115 patients with HIV infection from Hospital 
Dia were screened between February 2009 and August 2010. 
Among them, 111 patients met the study inclusion criteria 
and were assigned to either the intervention group (n=57) or 
control group (n=54). Four patients could not be included in 
the study because of obesity (n=3) and being older than 60 
(n=1). Consent was obtained from all patients participating 
in the study. During the study, 12 patients in the intervention 
group were excluded: six were transferred to another health 
care center, and six did not attend at least two pharmacist 
 appointments. From the control group, nine patients were 
excluded: seven were transferred to another health care  center, 
and two died. Thus, the final sample included 90 patients 
(n=45 for both groups). The average interval between visit 
one and visit two for both groups was 5.47±3.94 months, 
and the average duration of each visit was 1 hour. The aver-
age number of pharmacist appointments per patient in the 
intervention group was 3.0±1.1 (range =2–5).
Table 2 shows the baseline characteristics of the control 
and intervention groups. The groups were similar in age, sex, 
ethnicity, time of HIV diagnosis, treatment, and laboratory 
baseline values. The intervention group presented with a 
mean basal CD4+ count of 260.7 cells/mm3, and the control 
group presented with 228.9 cells/mm3. Eighty-nine percent 
of intervention group patients versus 93% of control group 
patients presented with comorbidities.
Table 3 shows DRPs, the primary end point. At visit one, 
5.2 (95% CI =4.1–6.2) potential DRPs per patient were found 
for a total of 227. Most of these DRPs (3.0 per patient) were 
due to adverse reactions. After pharmacist intervention, DRPs 
per patient decreased to 4.2 (95% CI =3.3–5.1, P=0.043), 
illustrating the relationship between potential DRPs observed 
before and after pharmacist intervention and their frequency 
in the study (in absolute numbers).
A total of 122 interventions were proposed, with an aver-
age of 2.7 interventions per patient. Among them, 33 (27%) 
were to solve DRPs, including 28 pharmacist–patient 
interventions. Seventy-nine (65%) interventions were to 
prevent DRPs, including 63 pharmacist–patient interventions. 
Ten (8%) interventions were related to improving quality of 
life. Figure 1 shows the most-performed pharmacist inter-
ventions and prevalence of pharmacist–patient/physician 
interventions. All pharmacist interventions were accepted by 
physicians, and among patients, the interventions were well 
accepted during the appointments, but compliance with the 
interventions was not measured.
Figure 2 shows a significant increase in the CD4+ 
T-lymphocyte count for the intervention group after the 
study period (P=0.015). However, no significant differ-
ence in CD4+ counts after the study was observed for the 
control group.
Variation of HIV viral load results before and after phar-
macist interventions for both groups were not significant 
(intervention group, P=0.154; control group, P=0.226). At 
baseline, 46% of the intervention group and 19% of the control 
group had an HIV viral load of 50 copies/mL; after the study 
period, these rates increased to 61% and 40%, respectively.
DRP reduction, total pharmacist interventions, increase of 
CD4+ T-lymphocyte count, and reduction in HIV viral load 
did not correlate significantly (data not shown).
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Table 2 Comparison of the initial characteristics (baseline) of the control group (n=45) and the intervention group (n=45)
Characteristics CG IG P-valuea
Age (average ± CI, years) 41.5 (39.2–43.8) 42.0 (39.1–44.9) 0.778
Men, % (n) 55.5 (25) 55.5 (25) 1.000
Ethnicity, % (n)
 Caucasian 64.4 (29) 57.8 (26) 0.522
 Biracial 24.4 (11) 28.9 (13) 0.816
 Asian 0.0 (0) 2.2 (1) 0.320
 Black 11.1 (5) 11.1 (5) 1.000
HIV diagnosis (average ± CI, years) 8.3 (6.9–9.7) 8.7 (6.2–11.2) 0.758
Treatment time (average ± CI, years) 7.5 (6.3–8.7) 6.7 (5.2–8.2) 0.409
Tablets per dayb (average ± CI, number) 8.6 (7.1–10.1) 8.6 (7.5–9.7) 0.961
CD4+ basal lymphocytes (average ± CI, cells/mm³) 228.9 (164.4–293.5) 260.7 (175.8–345.6) 0.589
Basal viral load 50 copies/mm³ (%) 34.0 44.0 0.285
Basal hemoglobin (average ± CI, g/dL) 12.4 (11.6–13.2) 12.7 (12.2–13.2) 0.411
Presented comorbidities, % (n) 93.3 (42) 88.8 (40) 0.464
 Hepatitis C 33.3 (15) 13.3 (6) 0.025
 Smoking 28.8 (13) 11.1 (5) 0.035
 Neurotoxoplasmosis 13.3 (6) 15.5 (7) 0.767
Antiretroviral regimen, %
 Zidovudine/lamivudine + efavirenz 15.5 15.4 0.910
 Lamivudine + tenofovir + lopinavir/ritonavir 22.2 7.7 0.212
 Zidovudine/lamivudine + tenofovir + lopinavir/ritonavir 11.1 15.4 0.753
 Zidovudine/lamivudine + lopinavir/ritonavir 11.1 0.0 0.198
 Lamivudine + tenofovir + efavirenz 11.1 15.4 0.753
 Others 28.9 46.1 0.150
Notes: aStudent’s t-test considering two-tailed test; bprescription medicines, not only antiretroviral agents.
Abbreviations: CG, control group: not assisted by the pharmacist; CI, confidence interval; HIV, human immunodeficiency virus; IG, intervention group: assisted by the 
pharmacist.
Table 3 Comparison of drug-related problems before and after the pharmaceutical intervention
DRPs 
Types
Before PI After PI P-valuea
Number Average (CI) Number Average (CI)
Unnecessary 1 0.0 (0.0–0.1) 1 0.0 (0.0–0.1) 1.000
Additional 70 1.6 (1.2–2.0) 50 1.3 (0.9–1.7) 0.016
Ineffective 7 0.2 (0.1–0.3) 4 0.1 (0.0–0.2) 0.183
Dosage too low 3 0.1 (0.0–0.2) 0 0.0 (0.0) 0.323
Adverse reaction 111 2.9 (2.4–3.4) 96 2.6 (2.1–3.1) 0.141
Dosage too high 17 0.5 (0.3–0.7) 17 0.5 (0.2–0.8) 1.000
Noncompliance 18 0.5 (0.2–0.7) 17 0.8 (0.3–0.8) 0.859
Total 227 5.2 (4.1–6.2) 171 4.2 (3.3–5.1) 0.043
Note: aStudent’s t-test considering two-tailed test
Abbreviations: CI, confidence interval; DRPs, drug-related problems; PI, pharmaceutical intervention.
Discussion
Pharmacist contributions to the optimization of drug therapy 
may be evaluated through indirect measures (eg, DRPs) 
and direct measures, which provide the most conclusive 
evidence (eg, clinical outcomes).32 A study with 70 patients 
who received pharmacist interventions during a 4-year period 
showed that direct patient care led to an increase in treatment 
compliance and clinical benefits and demonstrated that an 
average of 1.7 interventions per patient were needed.33
Data from the current study show that patients with HIV 
infection managed simultaneously by a clinical pharmacy 
team and their physicians benefited from a decrease in the 
number of DRPs. At visit one, a high number of potential 
DRPs per patient were found, which is consistent with a 
study where medical records were prospectively reviewed in 
83 patients with HIV infection who received ARV therapy for 
20 months; 176 DRPs were identified in 71 of these patients, 
including inappropriate prophylaxis for opportunistic infec-
tions, too-low and too-high dosages, adverse drug reactions 
due to ARV drugs, and drug–drug interactions between the 
ARV drug and another medication.7 In the current study, 
the most prevalent DRP identified was adverse reaction. 
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Figure 2 Comparison of the mean CD4+ count before and after the study period for the control group (n=45) and intervention group (n=45).
Notes: aStudent’s t-test considering two-tailed test; b95% confidence interval considered.
Other researchers have also found high frequencies of inap-
propriate dosage and safety problems.34,35 One showed that 
the most common issues in hospitalized patients with HIV 
infection were contraindicated drug–drug combinations and 
dosing errors.35
The current study shows that DRPs per patient decrease 
significantly with clinical pharmacist intervention, which 
is consistent with another study demonstrating that clinical 
pharmacist involvement leads to significantly more DRPs 
being identified compared with usual care.36 Other studies have 
demonstrated that clinical pharmacists not only can effectively 
identify, solve, and prevent clinically significant DRPs and their 
outcomes but also have assisted the multidisciplinary team in 
improving ARV treatment adherence and rational drug use and 
diminishing drug-related health problems.33,36,37
The detection of DRP reduction, however, is not  sufficient. 
It is also necessary to demonstrate positive clinical outcomes. 
The current study demonstrates that patients undergoing 
pharmaceutical care had a significant increase in CD4+ counts 
when compared before and after the study period, whereas the 
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control group did not show this increase. This difference in 
CD4+ count was the most relevant between the study groups. 
In the intervention group, the difference between CD4+ 
counts at both measured moments (ie, visits one and two) was 
∼51.3 cells/mm3. Immunologic responses of 50 cells/mm3 had 
previously been correlated with a reduced risk of developing 
opportunistic infections,38 suggesting a trend toward improve-
ment of ARV treatment adherence in the intervention group as 
previously demonstrated by other studies.4,6,15,33,39 Researchers 
demonstrated that patients with HIV under pharmaceutical 
care have significantly improved CD4+ counts, decreased 
HIV viral load, and fewer toxic effects related to ARV drugs.39 
 Toxicity reduction improves patient quality of life and treat-
ment adherence.40–42 A cohort study in 2,234 patients showed 
that those patients who had pharmacy team involvement in 
their care adhered more to ARV therapy than those who did 
not have pharmacy team involvement.43 On the contrary, the 
current study demonstrates that both the intervention and 
control groups had similar results relative to HIV viral load. 
Further studies are needed over a longer monitoring period 
to allow for a better analysis.
The clinical pharmacists in the cur rent study 
 performed 70% of the pharmacist–patient intervention. 
This finding demonstrates that patients with HIV need orien-
tation regarding ARV treatment, which clinical pharmacists 
are well qualified to provide.
This study is one of the first efforts in Brazil to analyze 
the contribution of a clinical pharmacy team to clinical and 
safety outcomes in patients with HIV receiving ARV therapy. 
We intentionally measured only clinical outcomes, such as 
CD4+ counts and DRPs, rather than subjective outcomes, 
such as quality of life, to show quantitatively the benefits of 
pharmaceutical care in this patient population.
This study suggests that pharmaceutical intervention can 
increase CD4+ T-lymphocyte counts and decrease DRPs. 
Aside from its limitations, the study contributes to the discus-
sion of clinical care in both national and international health 
care scenarios. The study also shows the importance of an 
optimal pharmaceutical care plan and that the distribution 
of ARV treatments should be associated with educational 
initiatives. Further studies are encouraged to confirm the 
initiative of this program.
Limitations
This study has several limitations. First, the patients were 
allocated for control or intervention groups based on conve-
nience sampling, which can lead to selection bias. Second, the 
pharmacists were not blinded, which may have influenced the 
DRP identification and quantification process. However, the 
pharmacists were not the same as those who interviewed 
the patients during their appointments, minimizing this 
influence. Third, it was not possible to quantify DRPs in the 
control group. Although the control group did not participate 
in pharmaceutical appointments, DRP quantification could 
have been obtained through medical chart revision. However, 
the medical charts were not complete and are not as useful 
for gathering accurate information as is a pharmaceutical 
appointment. Fourth, some relevant information that could 
contribute to the study was not obtained, such as pill count. 
Due to Hospital Dia characteristics and study requirements, 
all pharmacist appointments were performed by two phar-
macists, which is unusual in pharmaceutical care services 
owing to financial issues. These research singularities were 
a result of study adaptations to the requirements of Hospi-
tal Dia. Finally, CD4+ counts and comorbidities were not 
identical in both study groups at inclusion. However, the 
difference between the groups regarding CD4+ count was not 
statistically significant. These limitations are already being 
addressed by the research team in current studies.
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